Partners and Distributors

Pharmaxis selectively partners with pharmaceutical and biotechnology companies to further our clinical endeavours and business aims.


Our partners are:

Boehringer In May 2015 Boehringer Ingelheim acquired  the Pharmaxis phase 1 investigational drug PXS4728A to develop it for the treatment of the liver-related condition NASH. Read more.
Chiesi In December 2014 Pharmaxis and Chiesi Farmaceutici SpA entered into an exclusive distribution and supply agreement for the commercialisation of Bronchitol® (mannitol) in the United States. Chiesi is responsible for funding up to US$22 million of the cost of the phase 3 clinical trial of Bronchitol. Read more. 
Synairgen In August 2015 Pharmaxis  and UK biotechnology company Synairgen plc entered into a research collaboration to develop a selective inhibitor to the lysyl oxidase type 2 enzyme (LOXL2) to treat the fatal lung disease idiopathic pulmonary fibrosis (IPF). Read more.


Our global network of distributors provide logistical support services for our approved products in world markets. For more information on our distributors please see: